Biological Markers and Guided Therapy, Vol. 2, 2015, no. 1, 143 - 151
HIKARI Ltd, www.m-hikari.com
http://dx.doi.org/10.12988/bmgt.2015.51214

Early Tumoricidal Drug-Induced Cardiotoxicity Determination: Possibilities of Biological Markers

Alexander Berezin

Internal Medicine Department, State Medical University for Zaporozhye, 26 Mayakovsky Av., Zaporozhye, Postcode 69035, Ukraine

Abstract

Cardiotoxicity due to tumoricidal drug use is defined as an asymptomatic reduction in left ventricular (LV) ejection fraction (EF) of ≥10% to <55% or as a reduction of the LVEF of ≥5% to <55% with symptoms of heart failure (HF). The implementation in routine practices the highly tumoricidal anthracycline drugs, taxanes, and trastuzumab cause progressive LV dysfunction and symptomatic HF in dose-dependent manner. Despite there is potent reversibility of tumoricidal drug-induced cardiotoxicity, this adverse effect frequently consists continuously and might lead to limited response to medical treatment and worse survival sufficiently. The aim of the mini review is consideration the clinical evidence that supports the use of cardiac biomarkers for early detection of cardiotoxicity. The review is reported that the identification of cancer patient with increased risk of early cardiotoxicity would allow not only prevention and diagnosis of chemotherapy related cardiotoxicity but also administration of optimal dose and duration of chemotherapy. The predictive role of brain natriuretic peptides, cardiac troponins and inflammatory biomarkers (C-reactive protein) is discussed.

Keywords: cardiotoxicity; anti-neoplastic chemotherapy; biomarkers; natriuretic peptides; C-reactive protein; troponins; risk stratification

Introduction

Cardiotoxicity as resulting in anti-neoplastic chemotherapy, radiation therapy, and targeted agents is well recognized and frequently considered an expected adverse effect [1]. The implementation in routine practice the highly tumoricidal anthracicline

drugs, taxanes, and trastuzumab cause progressive left ventricular (LV) dysfunction and symptomatic heart failure (HF) in dose-dependent manner [2, 3]. The improved survival rate raises the likelihood that patients will experience wide spectrum cardiotoxicity: from asymptomatic diastolic dysfunction to acute severe HF [4]. Although reversibility of tumoricidal drug-induced cardiotoxicity is possible [5, 6], in generally, this adverse effect frequently consists continuously and might lead to limited response to medical treatment and worse survival sufficiently [7, 8]. Despite the majority of patients with LVEF decline from cancer therapy could achieve full LVEF recovery and complete their cancer therapy, there is no consensual agreement regarding strategy to management cardiac dysfunction in this patient population [9]. Additionally, there are no developed clinical guidelines for early detection of cardiotoxicity too. It has been suggested that biomarkers, most prominently brain natriuretic peptides (BNPs), cardiac troponins and inflammatory biomarkers (C-reactive protein, soluble ST2, galectin-3) might have utility to stratify the patients at risk of potential cardiac dysfunction at early stage before clinically manifestation [10, 11]. The aim of the mini review is consideration the clinical evidence that supports the use of cardiac biomarkers for early detection of cardiotoxicity.

Definition of cardiotoxicity

According Cardiac Review and Evaluation Committee criteria cardiotoxicity due to tumoricidal drug use is generally characterized by an asymptomatic reduction in LVEF of ≥10% to <55% or, less often, as a reduction of the LVEF of ≥5% to <55% with symptoms of HF [12]. The cardiac dysfunction associated with anthracycline therapy leads to significantly decline of LVEF and frequently associates with asymptomatic and symptomatic HF, whereas trastuzumab-induced cardiotoxicity is most often reversible upon discontinuation of treatment and initiation of standard medical care for HF [13, 14].

Molecular pathogenetic mechanisms underlying anthracycline-induced cardiac toxicity

It is well known that pivotal role in anthracycline-induced cardiotoxicity belongs to oxidative stress, which mediates worse of myofilament protein synthesis, destroying structured protein, and cytoskeleton, and as well as apoptosis of cardiac myocites [15-17]. Therefore, anthracycline is able to suppress reparative capable of cardiac myocites via inhibition of cardiac progenitor cells mobbing and differentiation [18, 19]. It has been suggested that calcium overload resulting in alterations in cardiac myocites metabolism leads to ultrastructural changes in cytoskeleton and mediates development of asymptomatic myocardial dysfunction and subsequently clinically manifested HF [20, 21]. Thus, molecules that are able reflect these multiple faces of pathophysiology of cardiotoxicity are considered potent surrogate candidates in biomarkers with diagnostic and predictive value.

Brain natriuretic peptides

Because of assessment of the LVEF fails to detect subtle alterations in cardiac function in chemotherapy-treated patients, BNPs could predict future cardiac dysfunction. Current clinical guidelines serve measurement of BNP as a marker of biomechanical stress for diagnostic and predictive value in generally population patients at high risk of HF development and in those who have acute or symptomatic chronic HF with volume overload [22-25]. Theoretically, cardiac dysfunction as result in chemotherapy might reflect in stretching of cardiac wall and secretion of BNP in circulation. However, the received results were controversial and frequently relate to treatment regime, the adjuvant setting and concomitant therapy. Sawaya et al [26] reported that NT-proBNP did not predict cardiotoxicity patients treated with anthracyclines and trastuzumab. Fallah-Rad et al [27] were not able to find sufficient changes in serum concentrations of troponin T, C-reactive protein, and BNP among trastuzumab-treated patients with human epidermal growth factor receptor II-positive ($HER2^+$) breast cancer.
Contrary, Cil et al [28] have found a closely association between higher NT-proBNP levels and reduced LVEF in asymptomatic breast cancer patients after doxorubicin administration. Authors have shown that NT-proBNP could be an early indication of subclinical acute anthracycline cardiotoxicity. Ürun et al [29] have believed that women with $HER2^+$ breast cancer treated with trastuzumab could early stratify at risk of cardiotoxicity with of NT-proBNP (> 300 ng/ml). Moreover, Horácek et al [30] have reported that transient elevation of NT-proBNP may indicate acute subclinical cardiotoxicity in anthracycline-treated patients with acute myeloid leukemia. Thus, it seems to be that NT-proBNP could be useful in the early detection of anthracycline cardiotoxicity [31], while trastuzumab-induced cardiotoxicity is probably not defined by measurement of serum NT-proBNP [32].

High-sensitivity cardiac troponins

The results regarding predictive value of high-sensitivity cardiac troponins in anthracycline and trastuzumab cardiotoxicity are controversial. This controversial relates that anthracyclines, even in higher cumulative doses, do not usually cause detectable acute injury to cardiomyocyte structure. Indeed, Horacek et al [32] reported that high-sensitivity cardiac troponin T was not elevated in patients treated for acute leukemia with anthracycline, although serum level of NT-proBNP was elevated sufficiently and could be useful in the early detection of anthracycline cardiotoxicity. In another study, in contrast to BNP, elevated high-sensitivity cardiac troponin I level was proposed an independent predictor of the development of cardiotoxicity at 6 months in cancer patients treated with anthracyclines and trastuzumab [25]. Additionally, there are evidences regarding that the early increase in high-sensitivity cardiac troponin I might offer additive information about the cardiotoxicity risk in cancer patients undergoing doxorubicin and trastuzumab therapy [33-35]. Overall, biochemical markers of

structural and functional myocardial damage, such as cardiac troponons, might have utility in cardiotoxicity monitoring in doxorubicin- and trastuzumab-treated individuals.

High-sensitivity C-reactive protein

High-sensitivity C-reactive protein (hs-CRP) is discussed a predictive biomarker of increased risk of cardiotoxicity among cancer patients treated with anthracycline and trastuzumab [36]. Onitilo et al [37] reported that elevated hs-CRP (≥3 mg/L) predicted decreased LVEF with a sensitivity of 92.9% and specificity of 45.7% in patients with early $HER2^+$ breast cancer. Interestingly, author found that the maximum hs-CRP value was observed a median of 78 days prior to detection of cardiotoxicity by decreased LVEF, and those with normal levels were at lower risk for cardiotoxicity. This result opens a perspective to regular monitoring of hs-CRP level for identifying women with early-stage breast cancer at low risk for asymptomatic trastuzumab-induced cardiotoxicity. In contrast, Lipshultz et al [38] did not find closely association increased hs-CRP with any echocardiographic variables in doxorubicin-treated subjects with acute lymphoblastic leukemia, although cardiac troponin T and NT-proBNP were related to an abnormal LV thickness-to-dimension ratio, suggesting LV remodeling. In general, definitive validation studies are required to fully establish clinical utility of hs-CRP in cancer patients as biomarker of cardiotoxicity.

Future perspectives

Because of biomechanical stress biomarkers (BNP, NT-proBNP), markers of myocardial injury (cardiac troponis) and inflammation (hs-CRP) are not specific for cardiotoxicity and might not help to sufficiently individualize treatment by immediately identifying cardiac injury and HF, novel biomarkers are discovered widely. It has been suggested that several cardiac biomarkers reflected inflammatory reactions and oxidative stress, i.e. growth differentiation factor-15, myeloperoxidase, and galectin-3, could useful for prediction of the risk of early cardiotoxicity. Probably, biomarkers of angiogenesis (placental growth factor), vascular remodeling (soluble fms-like tyrosine kinase receptor-1) might be demonstrated the benefit in this setting too. In this context, more investigations are required to consolidate our knowledge regarding utility of biomarkers of cardiotoxicity in cancer patients.

Conclusion

One can suggest that the identification of cancer patient with increased risk of early cardiotoxicity would allow not only prevention and diagnosis of chemotherapy related cardiotoxicity but also administration of optimal dose and duration of chemotherapy. However, the determining optimal biomarker(s) for risk stratification strategy is not completely clear and requires more investigations.

Funding and grants: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interests: not declared

References

[1] N. Howlader, A.M. Noone, M. Krapcho, J. Garshell, D. Miller, S.F. Altekruse, et al. (eds.), SEER Cancer Statistics Review, 1975-2012, National Cancer Institute, Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. http://seer.cancer.gov/csr/1975_2012/

[2] T. Marinko, J. Dolenc, C. Bilban-Jakopin, Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer, *Radiology and Oncology*, **48** (2014), no. 2, 105-112. http://dx.doi.org/10.2478/raon-2013-0040

[3] J.L. Patnaik, T. Byers, C. Diguiseppi, D. Dabelea, T.D. Denberg, Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study, *Breast Cancer Res.*, **13** (2011), R64. http://dx.doi.org/10.1186/bcr2901

[4] L.W. Jones, M.J. Haykowsky, J.J. Swartz, P.S. Douglas, J.R. Mackey, Early breast cancer therapy and cardiovascular injury, *J. Am. Coll. Cardiol.*, **50** (2007), 1435–1441. http://dx.doi.org/10.1016/j.jacc.2007.06.037

[5] M. Guglin, R. Cutro, J.D. Mishkin, Trastuzumab-induced cardiomyopathy, *J. Card. Fail.*, **14** (2008), 437–444. http://dx.doi.org/10.1016/j.cardfail.2008.02.002

[6] M.S. Ewer, M.T. Vooletich, J.B. Durand, M.L. Woods, J.R. Davis, V. Valero, D.J. Lenihan, Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment, *J. Clin. Oncol.*, **23** (2005), 7820–7826. http://dx.doi.org/10.1200/jco.2005.13.300

[7] M.J. Hooning, A. Botma, B.M. Aleman, M.H. Baaijens, H. Bartelink, J.G.M. Klijn, C.W. Taylor, F.E. van Leeuwen, Long-term risk of cardiovascular disease in 10-year survivors of breast cancer, *J. Natl. Cancer Inst.*, **99** (2007), 365–375. http://dx.doi.org/10.1093/jnci/djk064

[8] A. Thakur, RM. Witteles, Cancer therapy-induced left ventricular dysfunction: interventions and prognosis, *J. Card. Fail.*, **20** (2014), no. 3, 155-158. http://dx.doi.org/10.1016/j.cardfail.2013.12.018

[9] S. Geiger, V. Lange, P. Suhl, V. Heinemann, H.J. Stemmler, Anticancer therapy induced cardiotoxicity: review of the literature, *Anti-Cancer Drugs*, **21**

(2010), no. 6, 578-590. http://dx.doi.org/10.1097/cad.0b013e3283394624

[10] S. Tian, K.M. Hirshfield, S.K. Jabbour, D. Toppmeyer, B.G. Haffty, A.J. Khan, et al., Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients, *Front. Oncol.*, **4** (2014), 277. http://dx.doi.org/10.3389/fonc.2014.00277

[11] M.G. Khouri, P.S. Douglas, J.R. Mackey, M. Martin, J.M. Scott, M. Scherrer-Crosbie, L.W. Jones, Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues, *Circulation*, **126** (2012), no. 23, 2749-2763. http://dx.doi.org/10.1161/circulationaha.112.100560

[12] M. Martin, F.J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J.A. Garcia-Saenz, et al., Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations, *The Oncologist*, **14** (2009), 1–11. http://dx.doi.org/10.1634/theoncologist.2008-0137

[13] E. Tan-Chiu, G. Yothers, E. Romond, C.E. Geyer, Jr., M. Ewer, D. Keefe, R.P. Shannon, S.M. Swain, A. Brown, L. Fehrenbacher, V.G. Vogel, T.E. Seay, P. Rastogi, E.P. Mamounas, N. Wolmark, J. Bryant, Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31, *J. Clin. Oncol.*, **23** (2005), 7811–7819. http://dx.doi.org/10.1200/jco.2005.02.4091

[14] J. Ganame, P. Claus, B. Eyskens, A. Uyttebroeck, M. Renard, J. D'Hooge, M. Gewillig, B. Bijnens, G.R. Sutherland, L. Mertens, Acute cardiac functional and morphological changes after Anthracycline infusions in children, *Am. J. Cardiol.*, **99** (2007), 974–977. http://dx.doi.org/10.1016/j.amjcard.2006.10.063

[15] G.W. De Keulenaer, K. Doggen, K. Lemmens, The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy, *Circ. Res.*, **106** (2010), 35–46. http://dx.doi.org/10.1161/circresaha.109.205906

[16] C. Ozcelik, B. Erdmann, B. Pilz, N. Wettschureck, S. Britsch, N. Hubner, K.R. Chien, C. Birchmeier, A.N. Garratt, Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy, *Proc. Nat. Acad. Sci. USA*, **99** (2002), 8880–8885. http://dx.doi.org/10.1073/pnas.122249299

[17] C.C. Lim, C. Zuppinger, X. Guo, G.M. Kuster, M. Helmes, H.M. Eppenberger, T.M. Suter, R. Liao, D.B. Sawyer, Anthracyclines induce calpain-

dependent titin proteolysis and necrosis in cardiomyocytes, *J. Biol. Chem.*, **279** (2004), 8290–8299. http://dx.doi.org/10.1074/jbc.m308033200

[18] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, *Pharmacol Rev.*, **56** (2004), 185–229. http://dx.doi.org/10.1124/pr.56.2.6

[19] A. De Angelis, E. Piegari, D. Cappetta, L. Marino, A. Filippelli, L. Berrino, et al., Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function, *Circulation*, **121** (2010), 276–292. http://dx.doi.org/10.1161/circulationaha.109.895771

[20] E.T. Yeh, C.L. Bickford, Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management, *J. Am. Coll. Cardiol.*, **53** (2009), 2231–2247. http://dx.doi.org/10.1016/j.jacc.2009.02.050

[21] B. Chen, X. Peng, L. Pentassuglia, C.C. Lim, D.B. Sawyer, Molecular and cellular mechanisms of anthracycline cardiotoxicity, *Cardiovasc. Toxicol.*, **7** (2007), 114–121. http://dx.doi.org/10.1007/s12012-007-0005-5

[22] C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, et al., 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, *J. Am. Coll. Cardiol.*, **62** (2013), no. 16, e147–e239.

[23] K. Dworzynski, E. Roberts, A. Ludman, J. Mant, Guideline Development Group of the National Institute for Health and Care Excellence, Diagnosing and managing acute heart failure in adults: summary of NICE guidance, *BMJ*, **349** (2014), g5695. http://dx.doi.org/10.1136/bmj.g5695

[24] J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, K. Dickstein, et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Developed in collaboration with the Heart Failure Association (HFA) of the ESC, *Eur. J. Heart Fail.*, **14** (2012), no. 8, 803-869.

[25] G.W. Moe, J.A. Ezekowitz, E. O'Meara, S. Lepage, J.G. Howlett, S. Fremes, et al., The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications, *Can. J. Cardiol.*, **31** (2015), no. 1, 3-16. http://dx.doi.org/10.1016/j.cjca.2014.10.022

[26] H. Sawaya, I.A. Sebag, J.C. Plana, J.L. Januzzi, B. Ky, V. Cohen, et al., Early detection and prediction of cardiotoxicity in chemotherapy-treated patients, *Am. J. Cardiol.*, **107** (2011), no. 9, 1375-1380. http://dx.doi.org/10.1016/j.amjcard.2011.01.006

[27] N. Fallah-Rad, J.R. Walker, A. Wassef, M. Lytwyn, S. Bohonis, T. Fang, et al., The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy, *J. Am. Coll. Cardiol.*, **57** (2011), no. 22, 2263-2270. http://dx.doi.org/10.1016/j.jacc.2010.11.063

[28] T. Cil, A.M. Kaplan, A. Altintas, A.M. Akin, S. Alan, A. Isikdogan, Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: A prospective series, *Clin. Drug. Investig.*, **29** (2009), no. 2, 131-137. http://dx.doi.org/10.2165/0044011-200929020-00007

[29] Y. Ürun, G. Utkan, B. Yalcin, H. Akbulut, H. Onur, D.G. Oztuna, et al., The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer, *Exp. Oncol.*, **37** (2015), no. 1, 53-57.

[30] J.M. Horácek, R. Pudil, M. Tichý, L. Jebavý, A. Strasová, R. Praus, P. Zák, J. Malý, The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia, *Neoplasma*, **52** (2005), no. 5, 430-4.

[31] A. Kittiwarawut, Y. Vorasettakarnkij, S. Tanasanvimon, S. Manasnayakorn, V. Sriuranpong, Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction, *Asia Pac. J. Clin. Oncol.*, **9** (2013), no. 2, 155-161. http://dx.doi.org/10.1111/j.1743-7563.2012.01588.x

[32] J.M. Horacek, R. Pudil, L. Jebavy, M. Tichy, P. Zak, J. Maly, Assessment of anthracycline-induced cardiotoxicity with biochemical markers, Exp. Oncol., **29** (2007), no. 4, 309-313.

[33] B. Ky, M. Putt, H. Sawaya, B. French, J.L. Januzzi Jr., I.A. Sebag, et al., Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab, *J. Am. Coll. Cardiol.*, **63** (2014) no. 8, 809-816. http://dx.doi.org/10.1016/j.jacc.2013.10.061

[34] K. Katsurada, M. Ichida, M. Sakuragi, M. Takehara, Y. Hozumi, K. Kario, High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy, *Springerplus*, **3** (2014), 620. http://dx.doi.org/10.1186/2193-1801-3-620

[35] G. Pistillucci, A.A. Ciorra, V. Sciacca, M. Raponi, R. Rossi, E. Veltri, Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab, *Clin. Ter.*, **166** (2015), no. 1, e67-71.

[36] B. Zethelius, L. Berglund, J. Sundström, E. Ingelsson, S. Basu, A. Larsson, P. Venge, J. Arnlöv, Use of multiple biomarkers to improve the prediction of death from cardiovascular causes, *New Engl. J. Med.*, **358** (2008), no. 20, 2107-2116. http://dx.doi.org/10.1056/nejmoa0707064

[37] A.A. Onitilo, J.M. Engel, R.V. Stankowski, H. Liang, R.L. Berg, S.A. Doi, High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study, *Breast Cancer Res. Treat.*, **134** (2012) no. 1, 291-298. http://dx.doi.org/10.1007/s10549-012-2039-z

[38] S.E. Lipshultz, T.L. Miller, R.E. Scully, S.R. Lipsitz, N. Rifai, L.B. Silverman, et al., Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes, *J. Clin. Oncol.*, **30** (2012), no. 10, 1042-1049. http://dx.doi.org/10.1200/jco.2010.30.3404

Received: December 1, 2015; Published: December 30, 2015